CATX News & Events

Perspective Therapeutics announced certain business updates and strategic priorities for the next 12-18 months. Key updates include: Continued strong patient recruitment in neuroendocrine tumors for lead program VMT-alpha-NET sets the stage for submissions of robust clinical data package for presentation to more medical conferences in 2026, as well as regulatory engagement; VMT-alpha-NET continues to be well-tolerated and shows durable disease control and deepening of tumor response with longer follow-up as reported at ASCO-GI 2026; Clinical updates expected in mid to late 2026 for VMT01 targeting melanoma and PSV359 targeting FAP across multiple solid tumors, as well as potential additions to the clinical pipeline to be guided by first-in-human images

Perspective Therapeutics announced updated interim results from its ongoing Phase 1/2a clinical trial of 212PbVMT-alpha-NET in patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors are being presented as a poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, taking place January 8-10 in San Francisco, CA. Interim results with a data cut-off date of December 10, 2025 formed the basis of the ASCO-GI update. The presentation includes safety data from 56 patients across three dose cohorts who have received at least one treatment of 212PbVMT-alpha-NET, and efficacy analysis from two patients in Cohort 1 and 23 of the patients in Cohort 2. Results with a data cut-off date of September 12, 2025 were previously presented at the European Society for Medical Oncology Congress 2025 in October 2025. At ESMO, the Company reported safety data on 55 patients across three dose cohorts who had received at least one treatment of 212PbVMT-alpha-NET and interim efficacy data for two patients in Cohort 1 and 23 patients in Cohort 2.